Testosterone hormone replacement therapy: State-of-the-art and emerging technologies

被引:13
作者
Leichtnam, Marie-Laure
Rolland, Herve
Wuthrich, Patrick
Guy, Richard H. [1 ]
机构
[1] Univ Geneva, Fac Sci, Sch Pharmaceut Sci, CH-1211 Geneva 4, Switzerland
[2] Technol Servier, Drug Delivery Res Formulat Dept, F-45000 Orleans, France
[3] Univ Bath, Dept Pharm & Pharmacol, Bath BA2 7AY, Avon, England
关键词
drug delivery; hormone replacement therapy; skin; testosterone; transdermal drug delivery;
D O I
10.1007/s11095-006-0072-5
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In the human male, testosterone is the major circulating androgen. The clinical effects of androgen are numerous, and testosterone deficiency is associated with a number of clinical abnormalities. At present, a variety of preparations containing testosterone is available for the treatment of androgen deficiency. Ideally, those treatments have to produce and maintain physiologic serum concentrations of the hormone. This article reviews the current existing testosterone dosage forms on the market with their advantages and drawbacks and examines new and emerging technology developments concerning this therapy. In particular, the latest innovations in transdermal delivery are explored.
引用
收藏
页码:1117 / 1132
页数:16
相关论文
共 115 条
[1]   REACTION OF METHANESULFONYL NITRENE WITH BENZENE - ATTEMPTS TO GENERATE SULFONYL NITRENES FROM SOURCES OTHER THAN AZIDES [J].
ABRAMOVITCH, RA ;
BAILEY, TD ;
TAKAYA, T ;
UMA, V .
JOURNAL OF ORGANIC CHEMISTRY, 1974, 39 (03) :340-345
[2]   Development of a novel soft hydrogel for the Transdermal delivery of testosterone [J].
An, NM ;
Kim, DD ;
Shin, YH ;
Lee, CH .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2003, 29 (01) :99-105
[3]   Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system [J].
Arver, S ;
Dobs, AS ;
Meikle, AW ;
Allen, RP ;
Sanders, SW ;
Mazer, NA .
JOURNAL OF UROLOGY, 1996, 155 (05) :1604-1608
[4]   Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men [J].
Arver, S ;
Dobs, AS ;
Meikle, AW ;
Caramelli, KE ;
Rajaram, L ;
Sanders, SW ;
Mazer, NA .
CLINICAL ENDOCRINOLOGY, 1997, 47 (06) :727-737
[5]   PHYSIOLOGICAL TESTOSTERONE LEVELS IN NORMAL MEN SUPPRESS HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL LEVELS [J].
BAGATELL, CJ ;
KNOPP, RH ;
VALE, WW ;
RIVIER, JE ;
BREMNER, WJ .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (12) :967-973
[6]   Pharmacokinetics, safety and tolerability of three dosage regimens of buccal adhesive testosterone tablets in healthy men suppressed with leuprorelin [J].
Baisley, KJ ;
Boyce, MJ ;
Bukofzer, S ;
Pradhan, R ;
Warrington, SJ .
JOURNAL OF ENDOCRINOLOGY, 2002, 175 (03) :813-819
[7]  
BALSPRATSCH M, 1986, LANCET, V2, P943
[8]   Hypogonadism and androgen replacement therapy in elderly men [J].
Basaria, S ;
Dobs, AS .
AMERICAN JOURNAL OF MEDICINE, 2001, 110 (07) :563-572
[9]   Long-term effect of testosterone therapy on bone mineral density in hypogonadal men [J].
Behre, HM ;
Kliesch, S ;
Leifke, E ;
Link, TM ;
Nieschlag, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (08) :2386-2390
[10]   Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism:: phase I studies [J].
Behre, HM ;
Abshagen, K ;
Oettel, M ;
Hübler, D ;
Nieschlag, E .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1999, 140 (05) :414-419